Brind.

GSK and Ionis Pharmaceuticals report functional cure rates for hepatitis B drug

12 reports, 12 independent Updated Jun 16
Gone quiet Reached 11 outlets in its first 24 hours
Reports
12
Developments
4
Repetition
67%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 12 independent outlets

GSK and Ionis Pharmaceuticals reported pivotal Phase 3 results for bepirovirsen, a drug for chronic hepatitis B. In trials B-Well 1 and B-Well 2, 233 of 1,220 treated patients achieved a functional cure, compared to none in the placebo group. The drug is currently under fast-track review by the U.S. Food and Drug Administration, with a decision expected in October.

From yahoo.com, wokv.com

Why it matters

Some supportBrind's analysis of the reports

The drug works by binding to hepatitis B's genetic components, suppressing viral replication, and stimulating the immune system. Achieving a functional cure represents a major step in treating chronic hepatitis B, which can cause liver cancer or liver failure.

From fox4news.com, wokv.com

Who's involved

  • GSKCo-developed the bepirovirsen drug for hepatitis B
  • Ionis PharmaceuticalsCo-developed the bepirovirsen drug for hepatitis B

How it developed

Newest first. Tap a step to see who reported it.
  1. GSK and Ionis partner on bepirovirsen development, trading on Nasdaq.1 source
  2. GSK and Ionis Pharmaceuticals announced the co-development of the bepirovirsen drug for hepatitis B.1 source
  3. Findings on the co-developed bepirovirsen drug were presented at a scientific meeting in Barcelona.1 source
  4. Findings on the co-developed bepirovirsen drug were presented in Barcelona.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped